Bank of America Issues Pessimistic Forecast for Hims & Hers Health (NYSE:HIMS) Stock Price

Hims & Hers Health (NYSE:HIMS – Get Free Report) had its price objective decreased by stock analysts at Bank of America from $26.00 to $21.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm currently has a “neutral” rating on the stock. Bank of America‘s target price indicates a potential upside of 44.13% from the stock’s previous close.

Several other research analysts have also recently issued reports on the company. Deutsche Bank upped their price target on Hims & Hers Health from $25.00 to $26.00 and gave the company a “hold” rating in a report on Tuesday, August 11th. Citigroup reduced their price objective on Hims & Hers Health from $35.00 to $33.00 and set a “neutral” rating for the company in a research note on Tuesday, August 11th. Wall Street Zen raised Hims & Hers Health from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Morgan Stanley decreased their target price on Hims & Hers Health from $28.00 to $25.00 and set an “equal weight” rating on the stock in a report on Tuesday, November 10th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Hims & Hers Health in a research report on Wednesday, November 4th. Three analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $30.80.

Read Our Latest Stock Analysis on Hims & Hers Health

Hims & Hers Health Stock Down 9.1%

NYSE HIMS opened at $14.57 on Friday. The company has a debt-to-equity ratio of 3.85, a current ratio of 0.92 and a quick ratio of 0.84. The company’s 50 day simple moving average is $26.51 and its 200 day simple moving average is $26.43. Hims & Hers Health has a 12 month low of $13.74 and a 12 month high of $40.99. The company has a market capitalization of $3.42 billion, a P/E ratio of -17.55 and a beta of 2.53.

Hims & Hers Health (NYSE:HIMS – Get Free Report) last released its earnings results on Monday, November 9th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.06 by ($0.03). The business had revenue of $890.37 million for the quarter, compared to analyst estimates of $893.13 million. Hims & Hers Health had a negative net margin of 6.65% and a negative return on equity of 9.62%. The firm’s revenue for the quarter was up 48.6% on a year-over-year basis. During the same period in the prior year, the company earned $0.06 earnings per share. Equities research analysts expect that Hims & Hers Health will post -0.38 earnings per share for the current fiscal year.

Insider Activity

In other news, COO Michael Chi sold 14,027 shares of the business’s stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $28.39, for a total transaction of $398,226.53. Following the sale, the chief operating officer owned 456,660 shares in the company, valued at $12,964,577.40. The trade was a 2.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Oluyemi Okupe sold 29,277 shares of the business’s stock in a transaction that occurred on Tuesday, September 22nd. The shares were sold at an average price of $29.95, for a total transaction of $876,846.15. Following the sale, the chief financial officer owned 236,527 shares in the company, valued at $7,083,983.65. This represents a 11.01% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 105,041 shares of company stock valued at $2,764,840. Corporate insiders own 11.76% of the company’s stock.

Hedge Funds Weigh In On Hims & Hers Health

Several institutional investors and hedge funds have recently added to or reduced their stakes in HIMS. Blue Jean Financial LLC acquired a new stake in shares of Hims & Hers Health in the third quarter worth $3,159,000. B. Metzler seel. Sohn & Co. AG purchased a new position in shares of Hims & Hers Health during the second quarter valued at $2,992,000. FirstWave Capital Management LLC raised its position in Hims & Hers Health by 30.6% during the second quarter. FirstWave Capital Management LLC now owns 339,978 shares of the company’s stock valued at $11,787,000 after buying an additional 79,731 shares during the period. Prosperitas Financial LLC acquired a new position in Hims & Hers Health during the third quarter valued at $2,649,000. Finally, Concurrent Investment Advisors LLC raised its position in Hims & Hers Health by 109.8% during the second quarter. Concurrent Investment Advisors LLC now owns 35,272 shares of the company’s stock valued at $1,223,000 after buying an additional 18,459 shares during the period. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

About Hims & Hers Health

(Get Free Report)

Hims & Hers Health, Inc. operates a consumer-focused telehealth platform that connects patients with licensed healthcare providers and offers access to treatments and wellness products. Its services include online consultations, prescription care and over-the-counter products. The company serves a range of health needs, including hair loss, sexual health, skin care, mental health and weight management. Its platform also offers primary care and other services, with offerings varying by location and individual eligibility.

Further Reading

Analyst Recommendations for Hims & Hers Health (NYSE:HIMS)

Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.